Ann: Imugene Receives Positive Feedback From FDA, page-73

Back of the napkin scribble on what azer-cel could possibly be worth if it was to be brought by BP.

The current DLBCL market is projected to be worth $2.5B USD at peak sales per year, hypothetically if IMU could project that they could take 50% market share then we are looking in the neighborhood of $1.25B USD per year.. If we go by the notion that BP is willing to pay around 4 times peak sales that puts us at about a $5B USD valuation or $7.5B AUD. This doesn't take into account that we could ask a premium for our product as we have the ability to manufacture and deliver to BP. Rough numbers that you could be looking at is maybe $8B AUD, thus adding another $1 to the share price in 1-2 years time.

I would suggest that this is a pretty good investment considering its only targeting blood cancer and we still have multiple products targeting solid tumors.
I'd take an additional dollar on the SP any day of the week

I could be way off so open to other predictions